Saniona´s Clinical Trial in Hypothalamic Obesity Published in Scientific Journal
23 Mai 2022 - 8:00AM
Saniona´s Clinical Trial in Hypothalamic Obesity Published in
Scientific Journal
PRESS RELEASE
May 23,
2022
Saniona (OMX: SANION), a
clinical-stage biopharmaceutical
company focused on rare diseases, today announced
that the results from
the randomized controlled clinical trial
of Tesomet for weight loss in patients with
hypothalamic obesity has
been published in the
peer-reviewed scientific journal European Journal
of Endocrinology. The conclusion
is that the results are
encouraging
and support the continued investigation of Tesomet for
the treatment of
acquired hypothalamic
obesity.
Professor Ulla Feldt-Rasmussen, M.D., DMSc., Department of
Medical Endocrinology and Metabolism, Rigshospitalet Copenhagen
University Hospital and Principal Investigator on the Phase 2 study
stated, “Patients with hypothalamic obesity are faced with severe
and debilitating overweight for which there is no approved
treatments. I am highly encouraged by the study results, and I
believe that Tesomet may become a valuable treatment of this rare
disease, including management of the key characteristics of the
disease such as: persistent hunger, loss of appetite control,
uncontrollable weight gain and metabolic dysfunction. Equally
important is the favorable safety and tolerability profile of
Tesomet. These promising results warrant further studies and I look
forward to the continued development of Tesomet as a potential
first treatment to improve outcomes for patients with hypothalamic
obesity”.
The article in European Journal of Endocrinology
(https://doi.org/10.1530/EJE-21-0972) provides a description of the
clinical trial and the obtained results.
The data was reviewed in an oral presentation on May 22th 2022
at the European Congress of Endocrinology in Milano by co-author
Marianne Klose, M.D. Department of Medical Endocrinology and
Metabolism, Rigshospitalet Copenhagen University Hospital (ECE 2022
| ESE (ese-hormones.org).
For more information, please contact Thomas
Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com
This information was submitted for publication, through the
agency of the contact person set out above, at 8.00 CEST on 23 May
2022.
About Saniona Saniona is a clinical-stage
biopharmaceutical company with a mission to leverage its ion
channel targeting expertise to discover, develop and deliver
innovative rare disease treatments. The company’s most advanced
product candidate, Tesomet™, has been progressed into mid-stage
clinical trials for hypothalamic obesity and Prader-Willi syndrome,
serious rare disorders characterized by severe weight gain,
disturbances of metabolic functions and uncontrollable hunger.
These clinical trials are voluntarily paused due to funding
limitations and Saniona is actively exploring partnering
opportunities. Saniona has developed a proprietary ion channel drug
discovery engine anchored by IONBASE™, a database of more than
130,000 compounds, of which more than 20,000 are Saniona’s
proprietary ion channel modulators. Through its ion channel
expertise, Saniona is advancing two wholly owned ion channel
modulators, SAN711 and SAN903. SAN711 is in a Phase 1 clinical
trial and is positioned for the treatment of neuropathic pain
conditions, and SAN903 is in preclinical development for rare
inflammatory, fibrotic and hematological disorders. Saniona is
based in the Copenhagen area, Denmark, and is listed on Nasdaq
Stockholm Small Cap (OMX: SANION). Read more
at http://www.saniona.com.
- 20220523 HO data in European Journal of Endocrinology (UK)
Saniona Ab (LSE:0RQJ)
Historical Stock Chart
Von Jan 2025 bis Feb 2025
Saniona Ab (LSE:0RQJ)
Historical Stock Chart
Von Feb 2024 bis Feb 2025
